Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III optimized chemotherapy + Avastin strategy with or without Tarceva in metastatic colorectal cancer
2007-002797-56Phase 3Completed
- Sponsor
- GERCOR
- Start
- Jul 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab, erlotinib and capecitabine in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by GERCOR. Primary endpoint: Progression-free survival from randomization. Started Jul 2007; status: completed.
02
Drugs
bevacizumaberlotinibcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2007-002797-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002797-56.